8-K: Biote Subsidiary Recalls Hormone Pellets Over Metal Risk

Biote Corp.'s subsidiary, Asteria Health, initiated a voluntary recall of specific hormone pellet lots due to potential metal particulate matter, expecting a $1.3M Q4 charge and $1.0M in 2026 costs.

Summary

• F.H. Investments, Inc. (Asteria Health), a wholly-owned subsidiary of biote Corp., initiated a voluntary recall of specific lots of compounded bioidentical hormone pellets.
• The recall was initiated due to the potential presence of metal particulate matter in the pellets.
• The affected hormone pellets were shipped by Asteria Health between May 20, 2025, and January 19, 2026.
• The company has notified affected practitioners about the voluntary recall.
• The recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).
• Biote Corp. expects to record a one-time charge of approximately $1.3 million to its fourth-quarter cost of products for the write-off of impacted inventory.
• Additional costs related to the recall in 2026 are estimated to be approximately $1.0 million.
• The company does not believe its fourth-quarter business was impacted beyond the inventory write-off.
• Biote Corp. does not anticipate the recall will materially impact its ability to provide pellets to practitioner partners or the ability of practitioners to service patients.

Sentiment

Score: 4

Explanation: The voluntary recall of a core product due to quality issues, incurring immediate and future financial charges, is a significant negative event. While management asserts no material impact on future supply or patient service, the underlying product defect and associated costs weigh heavily on sentiment.

Positives

• The company does not anticipate the recall will materially impact its ability to provide pellets to its practitioner partners or the ability of practitioners to service patients.
• The recall is being conducted voluntarily and with the knowledge of the U.S. Food and Drug Administration (FDA), indicating proactive compliance.

Negatives

• A voluntary recall of specific lots of hormone pellets was initiated due to the potential presence of metal particulate matter.
• A one-time charge of approximately $1.3 million is expected to be recorded in the fourth quarter of 2025 related to the write-off of impacted inventory.
• Additional costs related to the recall, estimated at approximately $1.0 million, are expected to be incurred in 2026.

Risks

• Potential presence of metal particulate matter in hormone pellets, posing a safety risk to patients.
• Financial impact from inventory write-offs and additional recall-related costs.
• Reputational damage to biote Corp. and its subsidiary Asteria Health due to product quality issues.
• Increased scrutiny and potential regulatory actions from the U.S. Food and Drug Administration (FDA).
• General risks associated with heavy regulatory oversight in the industry.
• Potential for disruption in the supply of hormone pellets to practitioner partners, despite management's current assessment.
• Reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers, as noted in general forward-looking statements.

Future Outlook

The company expects to provide more details on the potential financial impact of this event when it reports its fourth-quarter results. Management does not believe the recall will materially impact its ability to provide pellets or the ability of practitioners to service patients, beyond the inventory write-off.

Management Comments

• "The Company does not believe that its fourth quarter business was impacted by the recall beyond the impact of the inventory write-off."
• "The Company does not anticipate the recall will materially impact its ability to provide pellets to its practitioner partners or the ability of practitioners to service patients."

Industry Context

This product recall occurs within the highly regulated bioidentical hormone therapy market. Such events can significantly impact patient trust and practitioner relationships, underscoring the critical importance of stringent quality control and regulatory compliance in the pharmaceutical and medical device sectors.

Comparison to Industry Standards

• N/A

Stakeholder Impact

• Shareholders: Will experience direct financial impact through a $1.3 million charge in Q4 2025 and an estimated $1.0 million in 2026 costs, potentially affecting stock price.
• Practitioners: May face disruption in their ability to provide specific hormone pellets and will need to manage patient communications regarding the recall.
• Patients: Those who received affected pellets face potential health risks from metal particulate matter and may experience anxiety or need to seek alternative treatments.
• Employees: Potential impact on manufacturing and quality control teams due to the recall investigation and remediation efforts.
• Regulatory Authorities (FDA): Will continue to monitor the recall process and may impose further requirements or investigations.

Next Steps

• The company will provide more details on the potential financial impact of this event when it reports its fourth-quarter results.

Key Dates

Recommendation

The voluntary recall of a key product due to quality concerns introduces uncertainty and direct financial costs ($1.3M in Q4 2025, $1.0M in 2026). While management asserts no material impact on future supply or patient service, the event itself is negative. Investors should hold to assess the full impact and the company's ability to mitigate reputational and operational risks, awaiting further details with Q4 results.

Keywords

biote Corp, BTMD, Asteria Health, hormone pellets, product recall, FDA, bioidentical hormones, manufacturing defect, product safety, medical device